Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XanaCIDD
ISRCTN52254972Phase 2Completed
- Sponsor
- Axiom Real-Time Metrics
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and Depression-related cognitive impairment comparing Xanamem with Placebo (2 arms). Primary endpoint: Attention and working memory at Week 10. Started Dec 2022; status: completed.
02
Drugs
emestedastat
03
Conditions
major depressive disorder (MDD)Depression-related cognitive impairment
Beyond the preview
Go deeper on ISRCTN52254972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52254972.